Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

NCT02445391 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT02445391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02445391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 20, 2015
Completion date
March 29, 2031
Enrollment
415 (actual)
Sites
1,024

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor negative, her2/neu negative, invasive breast carcinoma, progesterone receptor negative, stage ii breast cancer, stage iia breast cancer, stage iib breast cancer, stage iii breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, triple-negative breast carcinoma